Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lead Identification to Clinical Candidate Selection: Drugs for Chagas Disease

4 Oct 2014

Abstract excerpt

Chagas disease affects 8 million people worldwide and remains a main cause of death due to heart failure in Latin America. The number of cases in the United States is now estimated to be 300,000, but there are currently no Food and Drug Administration (FDA)-approved drugs available for patients with Chagas disease. To fill this gap, we have established a public-private partnership between the University of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Malaria Research and Control
Share to Research on Leishmaniasis Studies
Share to Trypanosoma species research and implications

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25281737
DOI: 10.1177/1087057114553103

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lead Identification to Clinical Candidate Selection: Drugs for Chagas DiseasePMID 25281737Read ↗

Phenotypic screening approaches for Chagas disease drug discovery.Semantic proximity Read ↗

Drug discovery for Chagas disease should consider Trypanosoma cruzi strain diversitySemantic proximity Read ↗

Drug screening and development cascade for Chagas disease: an update of in vitro and in vivo experimental models.Semantic proximity Read ↗

Discovery and Genetic Validation of Chemotherapeutic Targets for Chagas' DiseaseSemantic proximity Read ↗

Exploratory Study of Guanidine Derivatives as Novel Anti <i>Trypanosoma cruzi</i> ScaffoldsSemantic proximity Read ↗

Drug Discovery for Chagas Disease: Impact of Different Host Cell Lines on Assay Performance and Hit Compound SelectionSemantic proximity Read ↗

Two approaches to discovering and developing new drugs for Chagas diseaseSemantic proximity Read ↗

Optimization of antitrypanosomatid agents: identification of nonmutagenic drug candidates with in vivo activity.Semantic proximity Read ↗

Design or screening of drugs for the treatment of Chagas disease: what shows the most promise?Semantic proximity Read ↗

Identification of a Proteasome-Targeting Arylsulfonamide with Potential for the Treatment of Chagas’ DiseaseSemantic proximity Read ↗

Screening strategies to identify new chemical diversity for drug development to treat kinetoplastid infectionsSemantic proximity Read ↗

The current drug discovery landscape for trypanosomiasis and leishmaniasis: Challenges and strategies to identify drug targetsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.